Pfizer's non-COVID commercial portfolio is expanding rapidly, with new product launches and business development driving a 22% growth to nearly $12 billion annually. Meanwhile, Seagen's oncology drugs grew 20% and Biohaven's migraine treatments surged 41%, showing strong momentum beyond COVID-related products. Pfizer expects its COVID revenue to drop from $11 billion in 2024 to about $5 billion by 2026, increasing its reliance on these newer growth areas. Investors should watch if these growth rates continue, as management now views them as key performance indicators amid regulatory and market uncertainties affecting the COVID franchise.
Pfizer is maintained as a Buy due to its diversified and growing product portfolio, offering a 16% upside and about 7% dividend yield. The company is balancing losses from expiring patents and reduced COVID-19 sales with new growth products, cost con...
The European Commission has authorized Pfizer and BioNTech's updated COVID-19 vaccine for the 2026-2027 season, targeting the XFG variant of the virus. This vaccine is approved for individuals aged 6 months and older and is based on strong clinical a...
Willow Tree Research has started coverage on Pfizer with a contrarian BUY rating and a price target of $32 for the third to fourth quarter of 2026. The firm highlights Pfizer's strong non-COVID drug portfolio, including Padcev and Vyndamax, which are...
